In 2016, a phase II clinical trial involving 333 diabetic nephropathy patients(NCT02177786) suggested that 18 mg selonsertib (GS-4997, an ASK1 inhibitor) treatment for 48 weeks showed a 71% reduction in eGFR.536 Another phase IIb clinical trial assessing the effect of selonsertib on diabetic kidney disease is still ongoing (NCT04026165). Here, MAP3K5 is linked to diabetic kidney disease.